Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AbbVie Inc. stock logo
ABBV
AbbVie
$204.93
-0.6%
$199.66
$153.58
$218.66
$362.52B0.615.76 million shs9.25 million shs
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
$507.05
+2.2%
$550.11
$364.17
$616.00
$180.60B1.431.53 million shs1.42 million shs
Meta Platforms, Inc. stock logo
META
Meta Platforms
$583.93
-0.4%
$653.10
$414.50
$740.91
$1.48T1.2814.29 million shs13.20 million shs
These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AbbVie Inc. stock logo
ABBV
AbbVie
-1.79%+2.47%-1.43%+15.97%+14.04%
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
+0.22%-4.51%-13.40%-4.90%+25.70%
Meta Platforms, Inc. stock logo
META
Meta Platforms
+1.67%-6.44%-12.30%+0.08%+19.26%
Remove Ads
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AbbVie Inc. stock logo
ABBV
AbbVie
4.5313 of 5 stars
2.53.03.33.93.52.51.3
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
4.6155 of 5 stars
3.33.00.04.03.52.51.9
Meta Platforms, Inc. stock logo
META
Meta Platforms
4.0476 of 5 stars
3.43.01.70.02.83.31.9
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AbbVie Inc. stock logo
ABBV
AbbVie
2.92
Moderate Buy$211.453.18% Upside
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
2.67
Moderate Buy$611.8620.67% Upside
Meta Platforms, Inc. stock logo
META
Meta Platforms
2.86
Moderate Buy$718.5523.05% Upside

Current Analyst Ratings Breakdown

Latest ABBV, META, and ISRG Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/2/2025
Meta Platforms, Inc. stock logo
META
Meta Platforms
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$790.00 ➝ $790.00
3/31/2025
Meta Platforms, Inc. stock logo
META
Meta Platforms
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$810.00 ➝ $725.00
3/18/2025
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$707.00 ➝ $600.00
3/18/2025
Meta Platforms, Inc. stock logo
META
Meta Platforms
KeyCorp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$750.00 ➝ $710.00
3/17/2025
AbbVie Inc. stock logo
ABBV
AbbVie
Erste Group Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
3/17/2025
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
Erste Group Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
3/17/2025
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$666.00 ➝ $605.00
3/5/2025
AbbVie Inc. stock logo
ABBV
AbbVie
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$210.00 ➝ $240.00
3/4/2025
AbbVie Inc. stock logo
ABBV
AbbVie
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$200.00 ➝ $223.00
2/11/2025
Meta Platforms, Inc. stock logo
META
Meta Platforms
Tigress Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingStrong-Buy ➝ Strong-Buy
2/11/2025
Meta Platforms, Inc. stock logo
META
Meta Platforms
Tigress Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetStrong-Buy ➝ Strong-Buy$645.00 ➝ $935.00
(Data available from 4/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AbbVie Inc. stock logo
ABBV
AbbVie
$56.33B6.44$15.15 per share13.53$1.90 per share107.86
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
$8.35B21.62$6.68 per share75.93$46.41 per share10.93
Meta Platforms, Inc. stock logo
META
Meta Platforms
$164.50B8.99$25.83 per share22.61$72.08 per share8.10
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AbbVie Inc. stock logo
ABBV
AbbVie
$4.28B$2.4085.3914.661.627.59%296.28%12.65%4/25/2025 (Estimated)
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
$2.32B$6.4179.1066.455.8527.81%14.55%12.88%4/22/2025 (Estimated)
Meta Platforms, Inc. stock logo
META
Meta Platforms
$62.36B$23.9224.4119.331.4237.91%38.17%25.31%4/30/2025 (Estimated)

Latest ABBV, META, and ISRG Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
4/30/2025N/A
Meta Platforms, Inc. stock logo
META
Meta Platforms
$5.33N/AN/AN/A$41.45 billionN/A
4/25/2025N/A
AbbVie Inc. stock logo
ABBV
AbbVie
$2.51N/AN/AN/A$12.91 billionN/A
4/22/2025N/A
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
$1.71N/AN/AN/A$2.19 billionN/A
1/31/2025Q4 24
AbbVie Inc. stock logo
ABBV
AbbVie
$2.98$2.16-$0.82-$0.02$14.81 billionN/A
1/29/2025Q4 2024
Meta Platforms, Inc. stock logo
META
Meta Platforms
$6.75$8.02+$1.27$8.02$46.96 billionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AbbVie Inc. stock logo
ABBV
AbbVie
$6.563.20%+6.04%273.33%53 Years
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
N/AN/AN/AN/AN/A
Meta Platforms, Inc. stock logo
META
Meta Platforms
$2.100.36%N/A8.78%N/A

Latest ABBV, META, and ISRG Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/13/2025
AbbVie Inc. stock logo
ABBV
AbbVie
quarterly$1.643.4%4/15/20254/15/20255/15/2025
2/13/2025
Meta Platforms, Inc. stock logo
META
Meta Platforms
quarterly$0.52500.29%3/14/20253/14/20253/26/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AbbVie Inc. stock logo
ABBV
AbbVie
17.94
0.66
0.55
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
N/A
4.07
3.22
Meta Platforms, Inc. stock logo
META
Meta Platforms
0.16
2.98
2.98

Institutional Ownership

CompanyInstitutional Ownership
AbbVie Inc. stock logo
ABBV
AbbVie
70.23%
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
83.64%
Meta Platforms, Inc. stock logo
META
Meta Platforms
79.91%

Insider Ownership

CompanyInsider Ownership
AbbVie Inc. stock logo
ABBV
AbbVie
0.08%
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
0.70%
Meta Platforms, Inc. stock logo
META
Meta Platforms
13.71%
CompanyEmployeesShares OutstandingFree FloatOptionable
AbbVie Inc. stock logo
ABBV
AbbVie
50,0001.77 billion1.76 billionOptionable
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
12,100356.18 million352.97 millionOptionable
Meta Platforms, Inc. stock logo
META
Meta Platforms
74,0672.53 billion2.19 billionOptionable

Recent News About These Companies

Looking Ahead to the Q1 Earnings Season
UFC partners with Meta to elevate fan experiences
Meta signs multi-year partnership with UFC
Meta's head of AI research stepping down

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
AbbVie stock logo

AbbVie NYSE:ABBV

$204.93 -1.34 (-0.65%)
Closing price 03:58 PM Eastern
Extended Trading
$205.05 +0.12 (+0.06%)
As of 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Intuitive Surgical stock logo

Intuitive Surgical NASDAQ:ISRG

$507.05 +10.69 (+2.15%)
Closing price 04:00 PM Eastern
Extended Trading
$496.86 -10.20 (-2.01%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung. It also provides a suite of stapling, energy, and core instrumentation for its multi-port da Vinci surgical systems; progressive learning pathways to support the use of its technology; infrastructure of service and support specialists, a complement of services to its customers, including installation, repair, maintenance, 24/7 technical support, and proactive system health monitoring; and integrated digital capabilities providing connected offerings, streamlining performance for hospitals with program-enhancing insights. The company sells its products through direct sales organizations, such as capital and clinical sales teams. It has a collaboration agreement with FluoGuide A/S for head & neck cancer. The company was incorporated in 1995 and is headquartered in Sunnyvale, California.

Meta Platforms stock logo

Meta Platforms NASDAQ:META

$583.93 -2.07 (-0.35%)
Closing price 04:00 PM Eastern
Extended Trading
$555.92 -28.01 (-4.80%)
As of 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Meta Platforms, Inc. engages in the development of products that enable people to connect and share with friends and family through mobile devices, personal computers, virtual reality headsets, and wearables worldwide. It operates in two segments, Family of Apps and Reality Labs. The Family of Apps segment offers Facebook, which enables people to share, discuss, discover, and connect with interests; Instagram, a community for sharing photos, videos, and private messages, as well as feed, stories, reels, video, live, and shops; Messenger, a messaging application for people to connect with friends, family, communities, and businesses across platforms and devices through text, audio, and video calls; and WhatsApp, a messaging application that is used by people and businesses to communicate and transact privately. The Reality Labs segment provides augmented and virtual reality related products comprising consumer hardware, software, and content that help people feel connected, anytime, and anywhere. The company was formerly known as Facebook, Inc. and changed its name to Meta Platforms, Inc. in October 2021. The company was incorporated in 2004 and is headquartered in Menlo Park, California